A detailed history of Black Rock Inc. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Black Rock Inc. holds 11,552,066 shares of ABUS stock, worth $36.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,552,066
Previous 10,404,619 11.03%
Holding current value
$36.7 Million
Previous $26.8 Million 32.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.52 - $3.63 $2.89 Million - $4.17 Million
1,147,447 Added 11.03%
11,552,066 $35.7 Million
Q1 2024

May 10, 2024

BUY
$2.26 - $2.92 $32,360 - $41,811
14,319 Added 0.14%
10,404,619 $26.8 Million
Q4 2023

Feb 13, 2024

BUY
$1.69 - $2.54 $196,308 - $295,043
116,159 Added 1.13%
10,390,300 $26 Million
Q3 2023

Nov 13, 2023

BUY
$1.9 - $2.27 $578,766 - $691,473
304,614 Added 3.06%
10,274,141 $20.9 Million
Q2 2023

Aug 11, 2023

BUY
$2.24 - $3.06 $3.37 Million - $4.61 Million
1,505,441 Added 17.79%
9,969,527 $22.9 Million
Q1 2023

May 12, 2023

SELL
$2.23 - $3.1 $526,962 - $732,548
-236,306 Reduced 2.72%
8,464,086 $25.6 Million
Q4 2022

Feb 13, 2023

BUY
$1.91 - $2.85 $2.35 Million - $3.51 Million
1,232,574 Added 16.51%
8,700,392 $20.3 Million
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $136,420 - $208,984
-72,564 Reduced 0.96%
7,467,818 $14.3 Million
Q2 2022

Aug 12, 2022

BUY
$1.98 - $3.17 $1.42 Million - $2.27 Million
715,553 Added 10.48%
7,540,382 $20.4 Million
Q1 2022

May 12, 2022

BUY
$2.42 - $3.98 $1.59 Million - $2.62 Million
658,480 Added 10.68%
6,824,829 $20.3 Million
Q4 2021

Feb 10, 2022

BUY
$3.11 - $4.61 $718,864 - $1.07 Million
231,146 Added 3.89%
6,166,349 $24 Million
Q3 2021

Nov 09, 2021

BUY
$2.65 - $4.62 $264,019 - $460,290
99,630 Added 1.71%
5,935,203 $25.5 Million
Q2 2021

Aug 11, 2021

BUY
$2.5 - $3.51 $14.6 Million - $20.5 Million
5,835,573 New
5,835,573 $17.7 Million

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $477M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.